EXHIBIT 2

AstraZeneca Pharmaceuticals

Seroquel™
(Quetiapine)

Commercial Support Team - Technical Document (TD004)

BPRS meta-analysis

Request From:

Date Requested:

Statistician/Statistical Programmer Responsible: Rob Hemmings / Karen Melvin

1 Source of Data

Data for these analyses comes from mdata.bprs (a dataset stored in the CDE within the CST directory). This is a pooled dataset of 12 trials, each of which had either BPRS or PANSS as an endpoint. These trials represent all available data on BPRS scores from the Seroquel clinical trial program.

The creation of this dataset (handling of missing data, timing of endpoint etc.) is described in a document produced by Karen Melvin. This document is held in S:\d5077zfiles\cst\dataset creation.doc.

2 Design of Trials/ Analysis Methods

2.1 Study Design

Ten studies were selected to be used in this analysis, these are listed below:

5077IL/0004, 5077IL/0006, 204636/0007, 204636/0008, 5077IL/0013, 5077IL/0014, 5077IL/0050, 5077IL/0052, 5077IL/0053, 5077IL/0054.

The two trials omitted from the original dataset were trials 5077IL/0012 and 5077IL/0015. The former because there was no internal comparator (making model fitting difficult) and the latter because of significantly different entry criteria.

In 5 of these 10 trials, the BPRS questionnaire was used as an endpoint in the trial. In the remaining 5 trials, BPRS scores have been derived from the PANSS questionnaire which was a trial endpoint.

Comparators
The analyses performed compare Seroquel separately with each of placebo; Haloperidol; Chlorpromazine; Risperidone and 'other typicals' (defined as either Haloperidol or Chlorpromazine). Four of the trials contained comparative data against placebo; 4 against Haloperidol; 2 against Chlorpromazine; 1 against Risperidone and 6 against 'other typicals'.

Seroquel Dose

A range of doses of Seroquel were used in the above-mentioned studies, therefore each comparison was performed twice with respect to level of Seroquel dose. The first used all patients receiving therapeutic doses of Seroquel (150-750mg/day - labeled 'all doses'), the second used only patients receiving high-dose Seroquel (at least 400 mg/day - labeled 'high dose').

Categories of BPRS

The 18 point BPRS scale can either be assessed as a whole or can be sub-divided into separate item or factor scores. Assessed in these analyses were:

- Factor I (Somatic concern; Anxiety; Guilt feeling; Depressive mood) - baseline ≥ 8;
- Factor V (Hostility; Suspiciousness; Uncooperativeness) - baseline ≥ 6;
- Mood Cluster (Depressive mood; Anxiety; Guilt feelings; Tension) - baseline ≥ 8;
- Hostility Cluster (Anxiety; Tension; Hostility; Suspiciousness; Uncooperativeness; Excitement) - baseline ≥ 12;
- Hostility Item - baseline ≥ 3;
- Anxiety Item - baseline ≥ 3;
- Total BPRS score - baseline ≥ 36.

Patient Population

Though each of the above-mentioned trials may have slightly different patient populations, they were considered suitable for inclusion to this meta-analysis.
For inclusion to the analysis of each of the above categories, patients were required to be symptomatic in that category. Therefore, patients were not included in the analysis of a particular category unless their baseline score was at least that denoted above (note baselines are denoted as totals within each category). In addition, patients were excluded if their disease type did not match that recognised for Seroquel use in Europe.

2.2 Analysis Methods

Two endpoints were assessed in this meta-analysis.

Firstly, a 'change from baseline' score. This was calculated separately for each category and analysed via analysis of covariance (ANCOVA) using PROC MIXED in SAS, with the baseline appropriate to that category included in the model as a covariate. A term was also included in the model for 'trial'. Also assessed were trial*treatment and covariate*treatment interactions, though these were subsequently dropped from the model unless a consistent pattern of significance of these terms could be identified across each of the endpoints assessed. The standard checks of normality assumptions behind ANCOVA were performed.

Secondly the 'proportion of responders' was analysed. A responder was defined as any patient with at least a 40% drop in score from baseline to endpoint. These data were analysed using PROC GENMOD in SAS. The model used was similar to that described for the change from baseline endpoint above.

For each endpoint, both an 'observed cases' (OC) and a 'last value carried forward' (LVCF) analysis was performed.

In total, this BPRS meta-analysis has involved 7 categories of the BPRS scale, each to be assessed against 5 comparators, using 2 endpoints, each derived in two different ways (OC and LVCF). Each analysis was then performed for 2 cuts of the SEROQUEL data (by mean dose received). This makes a total of 280 separate p-values being generated. By chance alone we expect 1 in 20 p-values to be significant, therefore isolated significant p-values will be ignored, instead interpretation of the analyses will look for patterns of significant results, either across particular categories of the BPRS or against particular comparators.

2.3 Details of SAS programs

All analysis programs are stored in the CDE under the CST directory (s:\d5077\filesm\CST).

The programs used to create the mdata.bprs dataset are described in Karen's document. The programs performing the statistical analyses are:

- TD4_X1 - change from baseline analysis;
- TD4_X1A - change from baseline analysis (high doses of SEROQUEL);
- TD4_X1B - change from baseline analysis ('other typicals');
- TD4_X1C - change from baseline analysis (high dose of SEROQUEL versus 'other typicals);
- TD4_X2 - proportion of responders;
- TD4_X2A - proportion of responders (high doses of SEROQUEL);
- TD4_X2B - proportion of responders ('other typicals');
- TD4_X2C - proportion of responders (high dose of SEROQUEL versus 'other typicals).

In addition to this, baseline scores were investigated to ensure that BPRS scores derived respectively from BPRS and PANSS questionnaires could be combined. The programs producing these baseline plots are: TD4_BASE; TD4_2BAS.

3 Results

As described above, a very large number of analyses have been performed on these data, so the results of the analyses will necessarily be described in general terms. Initially, significant results will be discussed. Any trends observed in the data will then be highlighted.

<u>Change from baseline</u>

In each of the 7 categories, Seroquel proved to be significantly better than placebo (regardless of whether 'all doses' or only high-doses of Seroquel were used). In each case this improvement was observed using an LVCF approach, however for total

BPRS score using all Seroquel data, this result was supported by the observed cases analysis.
The pattern was less obvious when Seroquel was compared with Haloperidol. Against 'all doses' of Seroquel, each of the 3 significant p-values generated was in favour of Haloperidol (Total BPRS, Factor V and Hostility Cluster). There was no evidence of significant differences between the treatments when Haloperidol was compared to high-dose Seroquel.
No statistically significant differences were observed for any of the categories when Seroquel was compared with Chlorpromazine.
Comparisons against Risperidone used only trial 5077IL/0053. Against 'all doses' of Seroquel, Risperidone showed significant improvement on Factor V scores and the Hostility Cluster. Against high-dose Seroquel only, these two categories were again significantly in favour of Risperidone, along with the Anxiety Item, Total BPRS and the Mood cluster.
Against either Chlorpromazine or Haloperidol, LVCF analyses showed a significant improvement against Seroquel for Total BPRS, Factor V and the Hostility Cluster, though these differences were removed when assessing high-dose of Seroquel only.

For 'all doses' of Seroquel, trends were observed for the Factor I cluster in which a positive, though non-significant estimate of treatment effect was observed. This was also true for the Mood cluster (with the exception of comparisons versus Risperidone). For high doses of Seroquel, the Factor I cluster again showed mainly positive treatment effects (excepting Risperidone), however no trends were apparent in any of the other categories.

A full set of results, showing least square mean changes from baseline for each treatment group, an estimate of treatment effect (difference in lsmeans) with 95% confidence interval and associated p-value are presented in Appendix A.

Proportion of responders

Seroquel ('all doses') proved to be significantly better than placebo for 4 of the 7 categories as assessed by this endpoint (total BPRS, Factor V, Hostility Cluster, Mood Cluster) and tended toward significance in the Anxiety and Hostility items. A very similar pattern was observed for high doses of Seroquel only against placebo. In each of the 4 cases the improvement was observed using an LVCF approach.
The pattern was less obvious when Seroquel was compared with Haloperidol. Against 'all doses' of Seroquel, only Factor V showed a significant difference between the treatments - in favour of Haloperidol. As for the change from baseline analysis, this difference disappeared when comparing against only high-doses of Seroquel.
Again, no statistically significant results were obtained when Seroquel was compared with Chlorpromazine.
Comparisons against Risperidone using all doses of Seroquel showed significant improvement for Risperidone on total BPRS, Factor V scores and the Hostility Cluster. Against high-dose Seroquel only, the Anxiety item, Factor I and Mood cluster scores were also significantly in favour of Risperidone.
Against either Chlorpromazine or Haloperidol, LVCF analyses showed a significant improvement against 'all doses' of Seroquel for Factor V, though this difference were removed when assessing high-dose of Seroquel only.

As above, the more positive trends for Seroquel were observed on the Factor I and Mood cluster items, though no significant differences were found in favour of Seroquel other than against placebo.

A full set of results, showing percentage of responders for each treatment group, odds ratios and 95% confidence intervals with associated p-value are presented in Appendix A.

The following table is an attempt to simplify the claims that could be obtained from these results. A ✓ is entered for those comparisons where we have a statistically significant benefit, be it with 'all doses' or with high dose Seroquel, and be it using observed cases or using LVCF. A ✗ marks those comparisons where a comparator has demonstrated significant superiority compared to Seroquel.

Table 1

Comparator	Category						
	Anxiety	Total BPRS	Factor I	Factor V	Hostility	Hostility Cluster	Mood Cluster
Placebo	✓	✓	✓	✓	✓	✓	✓
Haloperidol	-	✗	-	✗	-	✗	-
Chlorpromazine	-	-	-	-	-	-	-
Risperidone	✗	✗	✗	✗	-	✗	✗
Other typicals	-	✗	-	✗	-	✗	-

4 Conclusions

In terms of generating positive claims for Seroquel, these analyses seem somewhat disappointing. Although some trends in favour of Seroquel were observed in the Factor I and Mood cluster items, there was no evidence in these analyses of a significant benefit for using Seroquel over any other of the active agents assessed. There was, however, consistent evidence that Seroquel is better than placebo for a number of the BPRS sub-categories assessed.

There was little evidence of improvement with high-doses of Seroquel relative to including 'all doses' of Seroquel, though in the Haloperidol studies some of the statistically significant disadvantages were removed when looking at high doses only. In contrast, in the comparisons against Risperidone (trial 5077IL/0053), looking at high doses of Seroquel appears to give relatively worse results than looking at all patients together.

In general, the analysis of the two endpoints of mean change from baseline and proportion of responders gave similar conclusions.

5 References

No references were used.

Appendix A: Statistical Appendix

Index of Tables Created

TITLE

Key: VAR - Category of BPRS being assessed (Anxiety Item, Total BPRS; Factor I; Factor V; Hostility Item; Hostility Cluster; Mood Cluster).
COMP - Comparator
LSCOMP - least square mean of comparator
LSSER - least square mean of Seroquel
EST - Estimate of treatment effect (either difference in lsmeans or odds ratio)
P_T - p-value
LOWER / LCL - 95% lower confidence interval bound
UPPER / UCL - 95% upper confidence interval bound
ANAL - OBSERVED CASES or LVCF analysis
SIG - * denotes statistical significance
SERN - Number of patients on Seroquel
SERR - Number of responders on Seroquel
SER% - Percentage of responders on Seroquel
COMPN - Number of patients on comparator
COMPR - Number of responders on comparator
COMP% - Percentage of responders on comparator

TABLE T1 Change from baseline analyses - all doses of Seroquel

OBS	LSCOMP	VAR	COMP	LSSER	EST	P_T	LOWER	UPPER	ANAL	SIG
1	-1.92888240	ENDANX	PLA	-2.16321932	0.23433692	0.2397	-0.1574	0.6261	OBSERVED CASES	
2	-1.22148681	ENDANX	PLA	-1.65696543	0.43547863	0.0070	0.1198	0.7512	LVCF	*
3	-1.64311081	ENDANX	HAL	-1.81583045	0.17271963	0.2842	-0.1441	0.4895	OBSERVED CASES	
4	-1.09703883	ENDANX	HAL	-1.23353560	0.13649677	0.3027	-0.1234	0.3964	LVCF	
5	-1.87706692	ENDANX	CHL	-1.80553924	-0.07152768	0.7017	-0.4395	0.2964	OBSERVED CASES	
6	-1.52013169	ENDANX	CHL	-1.47974816	-0.04038353	0.8284	-0.4070	0.3263	LVCF	
7	-1.96801427	ENDANX	RIS	-2.00028493	0.03227066	0.8844	-0.4066	0.4712	OBSERVED CASES	
8	-1.46212777	ENDANX	RIS	-1.38227098	-0.07985680	0.7155	-0.5116	0.3518	LVCF	
9	-17.76054585	ENDBPRS	PLA	-24.83229285	7.07174700	0.0039	2.2999	11.8436	OBSERVED CASES	*
10	-3.29219461	ENDBPRS	PLA	-12.10226823	8.81007362	0.0001	5.4671	12.1531	LVCF	*
11	-20.50075645	ENDBPRS	HAL	-19.87384433	-0.62691212	0.6831	-3.6447	2.3909	OBSERVED CASES	
12	-13.24621220	ENDBPRS	HAL	-9.93053659	-3.31567561	0.0145	-5.9713	-0.6600	LVCF	*
13	-22.13053657	ENDBPRS	CHL	-21.67375945	-0.45677712	0.8012	-4.0275	3.1139	OBSERVED CASES	
14	-17.75196333	ENDBPRS	CHL	-17.26124270	-0.49072063	0.7930	-4.1681	3.1867	LVCF	
15	-23.87001671	ENDBPRS	RIS	-24.11188221	0.24186550	0.9019	-3.6315	4.1152	OBSERVED CASES	
16	-19.45877126	ENDBPRS	RIS	-16.29780780	-3.16096346	0.1581	-7.5608	1.2388	LVCF	
17	-5.97958774	ENDFI	PLA	-6.95215090	0.97256316	0.1030	-0.1984	2.1435	OBSERVED CASES	
18	-3.75138902	ENDFI	PLA	-5.26858020	1.51719118	0.0024	0.5412	2.4932	LVCF	*
19	-5.01792808	ENDFI	HAL	-5.52521580	0.50728772	0.2369	-0.3349	1.3495	OBSERVED CASES	
20	-3.20544661	ENDFI	HAL	-3.47503972	0.26959311	0.4574	-0.4425	0.9817	LVCF	
21	-5.59177074	ENDFI	CHL	-6.35956050	0.76778976	0.1385	-0.2509	1.7865	OBSERVED CASES	
22	-4.60027853	ENDFI	CHL	-5.12941442	0.52913590	0.3319	-0.5437	1.6019	LVCF	
23	-5.15051726	ENDFI	RIS	-5.96312710	0.81260984	0.2096	-0.4636	2.0888	OBSERVED CASES	
24	-4.25134959	ENDFI	RIS	-4.29459640	0.04324681	0.9417	-1.1229	1.2093	LVCF	
25	-3.39572940	ENDFV	PLA	-4.46652537	1.07079596	0.0867	-0.1559	2.2974	OBSERVED CASES	
26	-1.35968707	ENDFV	PLA	-3.06318005	1.70349297	0.0003	0.7818	2.6252	LVCF	*
27	-4.32580592	ENDFV	HAL	-4.09406696	-0.23173895	0.4981	-0.9038	0.4403	OBSERVED CASES	
28	-3.04323303	ENDFV	HAL	-1.67985602	-1.36337701	0.0001	-2.0111	-0.7157	LVCF	*
29	-4.94827119	ENDFV	CHL	-4.54810579	-0.40016540	0.3761	-1.2899	0.4896	OBSERVED CASES	
30	-3.68675735	ENDFV	CHL	-3.42537388	-0.26138347	0.5942	-1.2262	0.7034	LVCF	
31	-5.54643474	ENDFV	RIS	-4.64890205	-0.89753268	0.0453	-1.7758	-0.0192	OBSERVED CASES	*
32	-4.12803635	ENDFV	RIS	-2.76431072	-1.36372563	0.0113	-2.4150	-0.3124	LVCF	*
33	-1.24805589	ENDHOST	PLA	-1.63088616	0.38283027	0.2615	-0.2898	1.0555	OBSERVED CASES	
34	-0.46937795	ENDHOST	PLA	-1.05716657	0.58778862	0.0155	0.1129	1.0627	LVCF	*
35	-2.09204701	ENDHOST	HAL	-2.17564885	0.08360184	0.7463	-0.4267	0.5939	OBSERVED CASES	
36	-1.56003798	ENDHOST	HAL	-1.17563778	-0.38440019	0.1020	-0.8457	0.0769	LVCF	
37	-2.14402246	ENDHOST	CHL	-2.13340168	-0.01062078	0.9632	-0.4658	0.4445	OBSERVED CASES	
38	-1.70533282	ENDHOST	CHL	-1.58320219	-0.12213063	0.6438	-0.6430	0.3987	LVCF	

39	-2.38373083	ENDHOST	RIS	-2.27768313	-0.10604770	0.7365	-0.7367	0.5246	OBSERVED CASES	
40	-2.02228254	ENDHOST	RIS	-1.40345663	-0.61882591	0.1169	-1.3966	0.1590	LVCF	
41	-7.58622096	ENDJMCK	PLA	-9.20592510	1.61970414	0.1167	-0.4079	3.6473	OBSERVED CASES	
42	-1.58099388	ENDJMCK	PLA	-4.56653108	2.98553719	0.0002	1.4067	4.5644	LVCF	*
43	-7.81202611	ENDJMCK	HAL	-7.60864672	-0.20337939	0.7424	-1.4194	1.0127	OBSERVED CASES	
44	-4.81841620	ENDJMCK	HAL	-3.50475023	-1.31366597	0.0267	-2.4748	-0.1526	LVCF	*
45	-9.48084330	ENDJMCK	CHL	-8.21072808	-1.27011522	0.1128	-2.8427	0.3024	OBSERVED CASES	
46	-7.06886652	ENDJMCK	CHL	-5.94149790	-1.12736863	0.2196	-2.9311	0.6764	LVCF	
47	-10.06303733	ENDJMCK	RIS	-8.79758485	-1.26545248	0.1184	-2.8576	0.3267	OBSERVED CASES	
48	-7.72743912	ENDJMCK	RIS	-4.78555086	-2.94188826	0.0022	-4.8135	-1.0702	LVCF	*
49	-6.06556776	ENDMOOD	PLA	-6.74951208	0.68394433	0.2579	-0.5051	1.8730	OBSERVED CASES	
50	-3.12900293	ENDMOOD	PLA	-4.94488213	1.81587920	0.0001	0.8876	2.7442	LVCF	*
51	-5.02980482	ENDMOOD	HAL	-5.45043252	0.42062770	0.3317	-0.4306	1.2719	OBSERVED CASES	
52	-3.19803087	ENDMOOD	HAL	-3.29500962	0.09697875	0.7915	-0.6231	0.8171	LVCF	
53	-6.02250350	ENDMOOD	CHL	-6.43589786	0.41339435	0.4230	-0.6031	1.4298	OBSERVED CASES	
54	-4.94702421	ENDMOOD	CHL	-5.01676714	0.06974293	0.9007	-1.0306	1.1701	LVCF	
55	-5.80608660	ENDMOOD	RIS	-6.24701590	0.44092930	0.4473	-0.7039	1.5857	OBSERVED CASES	
56	-4.58206556	ENDMOOD	RIS	-4.48510122	-0.09696434	0.8646	-1.2167	1.0227	LVCF	

OBS	LSCOMP	VAR	COMP	LSSER	EST	P_T	LOWER	UPPER	SIG	ANAL
1	-1.79389637	ENDANX	CHLOR + HAL	-1.86827025	0.07437388	0.5665	-0.1805	0.3292		OBSERVED CASES
2	-1.34183576	ENDANX	CHLOR + HAL	-1.36361603	0.02178027	0.8554	-0.2129	0.2565		LVCF
3	-21.58305415	ENDBPRS	CHLOR + HAL	-21.36233494	-0.22071921	0.8578	-2.6396	2.1981		OBSERVED CASES
4	-15.56831038	ENDBPRS	CHLOR + HAL	-12.94068905	-2.62762133	0.0302	-5.0029	-0.2524	*	LVCF
5	-5.29156414	ENDFI	CHLOR + HAL	-5.85050268	0.55893853	0.1077	-0.1227	1.2406		OBSERVED CASES
6	-3.83463775	ENDFI	CHLOR + HAL	-4.02731873	0.19268098	0.5522	-0.4435	0.8288		LVCF
7	-4.73066465	ENDFV	CHLOR + HAL	-4.46158711	-0.26907754	0.3340	-0.8158	0.2777		OBSERVED CASES
8	-3.47305920	ENDFV	CHLOR + HAL	-2.41828126	-1.05477795	0.0004	-1.6334	-0.4762	*	LVCF
9	-2.22606169	ENDHOST	CHLOR + HAL	-2.36440571	0.13834401	0.4211	-0.2001	0.4768		OBSERVED CASES
10	-1.66087953	ENDHOST	CHLOR + HAL	-1.46361825	-0.19726128	0.3046	-0.5747	0.1802		LVCF
11	-8.71122711	ENDJMCK	CHLOR + HAL	-8.08021617	-0.63101094	0.2213	-1.6435	0.3815		OBSERVED CASES
12	-6.01005250	ENDJMCK	CHLOR + HAL	-4.55178363	-1.45826887	0.0078	-2.5312	-0.3853	*	LVCF
13	-5.54239435	ENDMOOD	CHLOR + HAL	-5.92187829	0.37948394	0.2860	-0.3188	1.0777		OBSERVED CASES
14	-3.98221893	ENDMOOD	CHLOR + HAL	-3.96771977	-0.01449915	0.9658	-0.6784	0.6494		LVCF

TABLE T2 Change from baseline analyses - high doses of Seroquel only

OBS	LSCOMP	VAR	COMP	LSSER	EST	P_T	LOWER	UPPER	ANAL	SIG
1	-1.86002641	ENDANX	PLA	-1.89606302	0.03603661	0.8789	-0.4310	0.5030	OBSERVED CASES	
2	-1.11975252	ENDANX	PLA	-1.78884859	0.66909607	0.0006	0.2921	1.0461	LVCF	*
3	-1.59109117	ENDANX	HAL	-1.64386973	0.05277856	0.7670	-0.2978	0.4033	OBSERVED CASES	
4	-1.06312514	ENDANX	HAL	-1.30147985	0.23835471	0.1093	-0.0536	0.5304	LVCF	
5	-1.89249276	ENDANX	CHL	-1.78497344	-0.10751932	0.5883	-0.4990	0.2840	OBSERVED CASES	
6	-1.54665474	ENDANX	CHL	-1.48872100	-0.05793374	0.7723	-0.4522	0.3363	LVCF	
7	-2.01077886	ENDANX	RIS	-1.34670550	-0.66407335	0.0196	-1.2188	-0.1093	OBSERVED CASES	*
8	-1.49368861	ENDANX	RIS	-1.06956530	-0.42412331	0.1523	-1.0071	0.1588	LVCF	
9	-12.37181763	ENDBPRS	PLA	-17.70516480	5.33334716	0.0633	-0.2998	10.9665	OBSERVED CASES	
10	1.92442320	ENDBPRS	PLA	-9.05845346	10.98287666	0.0001	6.9911	14.9746	LVCF	*
11	-20.60733481	ENDBPRS	HAL	-17.94615278	-2.66118203	0.1137	-5.9627	0.6404	OBSERVED CASES	
12	-13.07277770	ENDBPRS	HAL	-10.93796166	-2.13481604	0.1576	-5.0989	0.8292	LVCF	
13	-22.18010978	ENDBPRS	CHL	-21.09511723	-1.08499254	0.5766	-4.9115	2.7415	OBSERVED CASES	
14	-17.78622375	ENDBPRS	CHL	-17.94716357	0.16093982	0.9357	-3.7650	4.0869	LVCF	
15	-23.87226225	ENDBPRS	RIS	-16.11690026	-7.75536199	0.0010	-12.3094	-3.2013	OBSERVED CASES	*
16	-19.43587302	ENDBPRS	RIS	-14.03920633	-5.39666670	0.0483	-10.7530	-0.0403	LVCF	*
17	-5.33815164	ENDFI	PLA	-5.66256394	0.32441230	0.6460	-1.0717	1.7206	OBSERVED CASES	
18	-2.92912778	ENDFI	PLA	-4.78898154	1.85985376	0.0025	0.6620	3.0577	LVCF	*
19	-4.91747782	ENDFI	HAL	-5.01335594	0.09587812	0.8379	-0.8264	1.0181	OBSERVED CASES	
20	-3.14125964	ENDFI	HAL	-3.71357248	0.57231284	0.1683	-0.2429	1.3875	LVCF	
21	-5.61517512	ENDFI	CHL	-6.26132346	0.64614835	0.2370	-0.4298	1.7221	OBSERVED CASES	
22	-4.63766965	ENDFI	CHL	-5.20598269	0.56831304	0.3264	-0.5713	1.7079	LVCF	
23	-5.15138965	ENDFI	RIS	-4.17475898	-0.97663067	0.1900	-2.4464	0.4932	OBSERVED CASES	
24	-4.24152962	ENDFI	RIS	-4.07587467	-0.16565495	0.8215	-1.6166	1.2853	LVCF	
25	-2.47225948	ENDFV	PLA	-3.36632258	0.89406310	0.2675	-0.6957	2.4839	OBSERVED CASES	
26	0.05125015	ENDFV	PLA	-2.58746679	2.63871693	0.0001	1.4935	3.7839	LVCF	*
27	-4.36108417	ENDFV	HAL	-4.02115444	-0.33992973	0.3603	-1.0702	0.3904	OBSERVED CASES	
28	-2.99474409	ENDFV	HAL	-2.34345872	-0.65128537	0.0677	-1.3502	0.0476	LVCF	
29	-4.94358920	ENDFV	CHL	-4.31140900	-0.63218020	0.1962	-1.5938	0.3295	OBSERVED CASES	
30	-3.68852378	ENDFV	CHL	-3.38474114	-0.30378264	0.5655	-1.3438	0.7362	LVCF	
31	-5.57247882	ENDFV	RIS	-3.17936878	-2.39311003	0.0001	-3.4499	-1.3363	OBSERVED CASES	*
32	-4.15897803	ENDFV	RIS	-2.70767998	-1.45129805	0.0368	-2.8124	-0.0902	LVCF	*
33	-1.23889365	ENDHOST	PLA	-1.72895804	0.49006439	0.2205	-0.3017	1.2818	OBSERVED CASES	
34	-0.41106989	ENDHOST	PLA	-1.49663968	1.08556979	0.0002	0.5253	1.6459	LVCF	*
35	-2.11643366	ENDHOST	HAL	-2.13421944	0.01778577	0.9476	-0.5177	0.5533	OBSERVED CASES	

36	-1.57249014	ENDHOST	HAL	-1.52913520	-0.04335494	0.8571	-0.5178	0.4311	LVCF	
37	-2.15169346	ENDHOST	CHL	-2.08561463	-0.06607884	0.7969	-0.5743	0.4421	OBSERVED CASES	
38	-1.72271481	ENDHOST	CHL	-1.60957163	-0.11314318	0.6975	-0.6876	0.4613	LVCF	
39	-2.43329859	ENDHOST	RIS	-2.02240750	-0.41089109	0.3877	-1.3646	0.5428	OBSERVED CASES	
40	-2.02411142	ENDHOST	RIS	-1.85877596	-0.16533546	0.7800	-1.3501	1.0195	LVCF	
41	-5.60851358	ENDJMCK	PLA	-6.79468075	1.18616717	0.3366	-1.2490	3.6213	OBSERVED CASES	
42	0.15085958	ENDJMCK	PLA	-4.47356794	4.62442752	0.0001	2.7161	6.5328	LVCF	*
43	-7.94031667	ENDJMCK	HAL	-7.29773930	-0.64257737	0.3438	-1.9765	0.6913	OBSERVED CASES	
44	-4.74070420	ENDJMCK	HAL	-4.25545285	-0.48525135	0.4541	-1.7582	0.7877	LVCF	
45	-9.48625190	ENDJMCK	CHL	-7.97775099	-1.50850091	0.0808	-3.2040	0.1870	OBSERVED CASES	
46	-7.06362286	ENDJMCK	CHL	-5.97633527	-1.08728759	0.2691	-3.0210	0.8464	LVCF	
47	-10.12324070	ENDJMCK	RIS	-5.60285644	-4.52038426	0.0001	-6.4103	-2.6305	OBSERVED CASES	*
48	-7.80928475	ENDJMCK	RIS	-4.13101782	-3.67826693	0.0030	-6.0835	-1.2730	LVCF	*
49	-5.62749649	ENDMOOD	PLA	-5.45764233	-0.16985416	0.8098	-1.5648	1.2251	OBSERVED CASES	
50	-2.61444904	ENDMOOD	PLA	-4.82320777	2.20875873	0.0001	1.0947	3.3228	LVCF	*
51	-4.90700396	ENDMOOD	HAL	-4.77209872	-0.13490524	0.7806	-1.0875	0.8177	OBSERVED CASES	
52	-3.11911109	ENDMOOD	HAL	-3.62295343	0.50384234	0.2252	-0.3116	1.3193	LVCF	
53	-6.01787574	ENDMOOD	CHL	-6.34122818	0.32335243	0.5532	-0.7520	1.3987	OBSERVED CASES	
54	-4.96993289	ENDMOOD	CHL	-4.97172332	0.00179043	0.9976	-1.1695	1.1731	LVCF	
55	-5.79496411	ENDMOOD	RIS	-4.04830400	-1.74666011	0.0156	-3.1544	-0.3389	OBSERVED CASES	*
56	-4.55460111	ENDMOOD	RIS	-3.71002082	-0.84458028	0.2451	-2.2755	0.5863	LVCF	

OBS	LSCOMP	VAR	COMP	LSSER	EST	P_T	LOWER	UPPER	SIG	ANAL
1	-1.76707457	ENDANX	CHLOR + HAL	-1.75815550	-0.00891907	0.9494	-0.2852	0.2674		OBSERVED CASES
2	-1.34475999	ENDANX	CHLOR + HAL	-1.42217172	0.07741173	0.5584	-0.1823	0.3371		LVCF
3	-21.71790120	ENDBPRS	CHLOR + HAL	-20.06123241	-1.65666879	0.2168	-4.2892	0.9759		OBSERVED CASES
4	-15.71720341	ENDBPRS	CHLOR + HAL	-14.29704250	-1.42016091	0.2815	-4.0079	1.1676		LVCF
5	-5.28710769	ENDFI	CHLOR + HAL	-5.56411911	0.27701141	0.4618	-0.4626	1.0166		OBSERVED CASES
6	-3.85988690	ENDFI	CHLOR + HAL	-4.27867823	0.41879133	0.2505	-0.2964	1.1339		LVCF
7	-4.75713631	ENDFV	CHLOR + HAL	-4.33339252	-0.42374379	0.1629	-1.0197	0.1722		OBSERVED CASES
8	-3.51044253	ENDFV	CHLOR + HAL	-2.93657933	-0.57386319	0.0716	-1.1984	0.0507		LVCF
9	-2.23114003	ENDHOST	CHLOR + HAL	-2.31125371	0.08011368	0.6671	-0.2869	0.4471		OBSERVED CASES
10	-1.71941743	ENDHOST	CHLOR + HAL	-1.72362724	0.00420981	0.9832	-0.3886	0.3970		LVCF
11	-8.80937945	ENDJMCK	CHLOR + HAL	-7.77454339	-1.03483606	0.0645	-2.1320	0.0624		OBSERVED CASES
12	-6.03853602	ENDJMCK	CHLOR + HAL	-5.13024481	-0.90829122	0.1255	-2.0711	0.2545		LVCF
13	-5.54214234	ENDMOOD	CHLOR + HAL	-5.61075894	0.06861661	0.8604	-0.6982	0.8355		OBSERVED CASES
14	-4.00945108	ENDMOOD	CHLOR + HAL	-4.31670134	0.30725027	0.4142	-0.4314	1.0459		LVCF

TABLE T3 Proportion of responders - all doses of Seroquel

OBS	COMP	END	ANAL	EST	LCL	UCL	P	SERN	SERR	SER%	COMPN	COMPR	COMP%	SIG
1	PLA	RESPANX	OBSERVED CASES	0.74012	0.36442	1.50316	0.40512	160	68	42.5000	56	24	42.8571	
2	PLA	RESPANX	LVCF	0.62955	0.38382	1.03262	0.06682	307	99	32.2476	123	35	28.4553	
3	PLA	RESPBPRS	OBSERVED CASES	0.46342	0.21431	1.00210	0.05062	148	72	48.6486	41	15	36.5854	
4	PLA	RESPBPRS	LVCF	0.34725	0.19061	0.63258	0.00055	304	87	28.6184	115	17	14.7826	*
5	PLA	RESPFI	OBSERVED CASES	0.65689	0.31573	1.36670	0.26091	141	82	58.1560	49	28	57.1429	
6	PLA	RESPFI	LVCF	0.67151	0.41248	1.09322	0.10926	261	114	43.6782	108	43	39.8148	
7	PLA	RESPFV	OBSERVED CASES	0.56606	0.28394	1.12848	0.10596	144	82	56.9444	48	22	45.8333	
8	PLA	RESPFV	LVCF	0.46766	0.28284	0.77324	0.00305	288	106	36.8056	120	30	25.0000	*
9	PLA	RESPHOST	OBSERVED CASES	2.31667	0.86413	6.21083	0.09497	79	35	44.3038	26	17	65.3846	
10	PLA	RESPHOST	LVCF	0.73154	0.39894	1.34143	0.31225	171	73	42.6901	66	26	39.3939	
11	PLA	RESPJMCK	OBSERVED CASES	0.67637	0.32345	1.41436	0.29885	141	81	57.4468	46	25	54.3478	
12	PLA	RESPJMCK	LVCF	0.53356	0.32427	0.87796	0.01343	297	103	34.6801	121	32	26.4463	*
13	PLA	RESPMOOD	OBSERVED CASES	0.60295	0.27408	1.32642	0.20849	151	88	58.2781	45	27	60.0000	
14	PLA	RESPMOOD	LVCF	0.47078	0.28393	0.78059	0.00350	284	119	41.9014	116	38	32.7586	*
15	HAL	RESPANX	OBSERVED CASES	1.10065	0.66436	1.82346	0.70965	188	96	51.0638	131	78	59.5420	
16	HAL	RESPANX	LVCF	1.00224	0.69463	1.44607	0.99046	350	128	36.5714	229	99	43.2314	
17	HAL	RESPBPRS	OBSERVED CASES	0.82711	0.52225	1.30993	0.41843	209	117	55.9809	164	96	58.5366	
18	HAL	RESPBPRS	LVCF	1.04784	0.74126	1.48120	0.79132	381	129	33.8583	262	107	40.8397	
19	HAL	RESPFI	OBSERVED CASES	0.80527	0.50046	1.29573	0.37215	185	108	58.3784	151	83	54.9669	
20	HAL	RESPFI	LVCF	0.88699	0.62842	1.25195	0.49521	352	145	41.1932	260	106	40.7692	
21	HAL	RESPFV	OBSERVED CASES	1.14320	0.70212	1.86136	0.59052	190	117	61.5789	168	118	70.2381	
22	HAL	RESPFV	LVCF	1.53737	1.08756	2.17323	0.01488	359	138	38.4401	262	145	55.3435	*
23	HAL	RESPHOST	OBSERVED CASES	0.80849	0.32541	2.00871	0.64707	71	42	59.1549	61	43	70.4918	
24	HAL	RESPHOST	LVCF	1.16633	0.63650	2.13721	0.61853	153	72	47.0588	94	59	62.7660	
25	HAL	RESPJMCK	OBSERVED CASES	0.90595	0.56277	1.45843	0.68432	197	117	59.3909	163	102	62.5767	
26	HAL	RESPJMCK	LVCF	1.02574	0.72369	1.45384	0.88646	366	136	37.1585	264	117	44.3182	
27	HAL	RESPMOOD	OBSERVED CASES	0.83245	0.52485	1.32032	0.43584	196	111	56.6327	151	82	54.3046	
28	HAL	RESPMOOD	LVCF	0.91593	0.65226	1.28618	0.61217	367	144	39.2371	262	104	39.6947	
29	CHL	RESPANX	OBSERVED CASES	0.87515	0.47998	1.59568	0.66344	98	58	59.1837	86	49	56.9767	
30	CHL	RESPANX	LVCF	1.00451	0.60414	1.67019	0.98617	124	61	49.1935	120	60	50.0000	
31	CHL	RESPBPRS	OBSERVED CASES	1.00690	0.56956	1.78005	0.98113	111	64	57.6577	109	62	56.8807	
32	CHL	RESPBPRS	LVCF	0.97390	0.60221	1.57500	0.91413	141	68	48.2270	148	70	47.2973	
33	CHL	RESPFI	OBSERVED CASES	0.78230	0.38669	1.58265	0.49465	81	59	72.8395	70	47	67.1429	
34	CHL	RESPFI	LVCF	0.87010	0.49762	1.52139	0.62549	105	61	58.0952	98	53	54.0816	
35	CHL	RESPFV	OBSERVED CASES	1.62199	0.86998	3.02405	0.12807	99	61	61.6162	100	72	72.0000	
36	CHL	RESPFV	LVCF	1.39066	0.84854	2.27915	0.19075	128	64	50.0000	142	83	58.4507	
37	CHL	RESPHOST	OBSERVED CASES	0.94059	0.38535	2.29587	0.89299	57	44	77.1930	56	42	75.0000	
38	CHL	RESPHOST	LVCF	0.95070	0.48734	1.85460	0.88211	72	48	66.6667	85	55	64.7059	

39	CHL	RESPJMCK	OBSERVED CASES	1.54632	0.83661	2.85809	0.16429	106	66	62.2642	99	70	70.7071	
40	CHL	RESPJMCK	LVCF	1.32930	0.81525	2.16749	0.25381	132	67	50.7576	141	81	57.4468	
41	CHL	RESPMOOD	OBSERVED CASES	0.86218	0.43889	1.69372	0.66687	86	61	70.9302	81	55	67.9012	
42	CHL	RESPMOOD	LVCF	1.16473	0.67777	2.00154	0.58095	111	62	55.8559	112	66	58.9286	
43	RIS	RESPANX	OBSERVED CASES	1.05654	0.48008	2.32521	0.89129	56	38	67.8571	64	45	70.3125	
44	RIS	RESPANX	LVCF	1.04980	0.58503	1.88381	0.87059	92	47	51.0870	94	50	53.1915	
45	RIS	RESPBPRS	OBSERVED CASES	2.03711	0.98478	4.21394	0.05503	67	44	65.6716	87	69	79.3103	
46	RIS	RESPBPRS	LVCF	2.26644	1.29137	3.97777	0.00436	98	47	47.9592	111	75	67.5676	*
47	RIS	RESPFI	OBSERVED CASES	1.12183	0.50245	2.50477	0.77907	55	38	69.0909	60	43	71.6667	
48	RIS	RESPFI	LVCF	1.47727	0.81762	2.66911	0.19606	91	47	51.6484	90	55	61.1111	
49	RIS	RESPFV	OBSERVED CASES	2.77949	1.17282	6.58719	0.02023	64	46	71.8750	82	72	87.8049	*
50	RIS	RESPFV	LVCF	2.26563	1.27812	4.01611	0.00511	95	49	51.5789	113	80	70.7965	*
51	RIS	RESPHOST	OBSERVED CASES	0.81567	0.17382	3.82769	0.79617	18	15	83.3333	32	26	81.2500	
52	RIS	RESPHOST	LVCF	1.22882	0.40973	3.68531	0.71308	26	18	69.2308	41	30	73.1707	
53	RIS	RESPJMCK	OBSERVED CASES	2.64135	1.19359	5.84517	0.01655	73	51	69.8630	85	73	85.8824	*
54	RIS	RESPJMCK	LVCF	2.76130	1.59364	4.78449	0.00029	115	54	46.9565	113	80	70.7965	*
55	RIS	RESPMOOD	OBSERVED CASES	0.95115	0.43766	2.06714	0.89938	64	47	73.4375	72	53	73.6111	
56	RIS	RESPMOOD	LVCF	1.17261	0.66606	2.06441	0.58109	97	53	54.6392	104	62	59.6154	

OBS	COMP	END	ANAL	EST	LCL	UCL	P	SERN	SERR	SER%	COMPN	COMPR	COMP%	SIG
1	CHL + HAL	RESPANX	OBSERVED CASES	1.00005	0.68005	1.47063	0.99978	286	154	53.8462	217	127	58.5253	
2	CHL + HAL	RESPANX	LVCF	1.00444	0.74656	1.35139	0.97665	474	189	39.8734	349	159	45.5587	
3	CHL + HAL	RESPBPRS	OBSERVED CASES	0.89641	0.62734	1.28090	0.54817	320	181	56.5625	273	158	57.8755	
4	CHL + HAL	RESPBPRS	LVCF	1.02459	0.77376	1.35674	0.86535	522	197	37.7395	410	177	43.1707	
5	CHL + HAL	RESPFI	OBSERVED CASES	0.80208	0.54104	1.18907	0.27224	266	167	62.7820	221	130	58.8235	
6	CHL + HAL	RESPFI	LVCF	0.87916	0.65594	1.17834	0.38879	457	206	45.0766	358	159	44.4134	
7	CHL + HAL	RESPFV	OBSERVED CASES	1.32579	0.90544	1.94128	0.14721	289	178	61.5917	268	190	70.8955	
8	CHL + HAL	RESPFV	LVCF	1.48572	1.11989	1.97105	0.00605	487	202	41.4784	404	228	56.4356	*
9	CHL + HAL	RESPHOST	OBSERVED CASES	0.87307	0.46250	1.64812	0.67541	128	86	67.1875	117	85	72.6496	
10	CHL + HAL	RESPHOST	LVCF	1.06334	0.67852	1.66642	0.78875	225	120	53.3333	179	114	63.6872	
11	CHL + HAL	RESPJMCK	OBSERVED CASES	1.11128	0.76458	1.61519	0.58023	303	183	60.3960	262	172	65.6489	
12	CHL + HAL	RESPJMCK	LVCF	1.11776	0.84221	1.48346	0.44078	498	203	40.7631	405	198	48.8889	
13	CHL + HAL	RESPMOOD	OBSERVED CASES	0.84641	0.57930	1.23667	0.38870	282	172	60.9929	232	137	59.0517	
14	CHL + HAL	RESPMOOD	LVCF	0.97218	0.73004	1.29462	0.84689	478	206	43.0962	374	170	45.4545	

TABLE T4 Proportion of responders - high doses of Seroquel

OBS	COMP	END	ANAL		EST	LCL	UCL	P	SERN	SERR	SER%	COMPN	COMPR	COMP%	SIG
1	PLA	RESPANX	OBSERVED CASES	1.00609	0.42910	2.3589	0.98887	78	29	37.1795	56	24	42.8571		
2	PLA	RESPANX	LVCF	0.55862	0.29316	1.0645	0.07671	115	35	30.4348	123	35	28.4553		
3	PLA	RESPBPRS	OBSERVED CASES	0.57553	0.24076	1.3758	0.21407	73	31	42.4658	41	15	36.5854		
4	PLA	RESPBPRS	LVCF	0.28512	0.13993	0.5810	0.00055	112	34	30.3571	115	17	14.7826	*	
5	PLA	RESPFI	OBSERVED CASES	0.95408	0.41226	2.2080	0.91256	66	33	50.0000	49	28	57.1429		
6	PLA	RESPFI	LVCF	0.62615	0.33711	1.1630	0.13836	95	41	43.1579	108	43	39.8148		
7	PLA	RESPFV	OBSERVED CASES	0.58365	0.25353	1.3436	0.20562	68	38	55.8824	48	22	45.8333		
8	PLA	RESPFV	LVCF	0.32391	0.17223	0.6092	0.00047	106	45	42.4528	120	30	25.0000	*	
9	PLA	RESPHOST	OBSERVED CASES	3.05269	0.87224	10.6838	0.08079	39	18	46.1538	26	17	65.3846		
10	PLA	RESPHOST	LVCF	0.54936	0.25287	1.1935	0.13024	64	30	46.8750	66	26	39.3939		
11	PLA	RESPJMCK	OBSERVED CASES	0.78544	0.34015	1.8136	0.57163	73	41	56.1644	46	25	54.3478		
12	PLA	RESPJMCK	LVCF	0.37059	0.20183	0.6805	0.00137	113	47	41.5929	121	32	26.4463	*	
13	PLA	RESPMOOD	OBSERVED CASES	0.94119	0.39114	2.2647	0.89238	73	35	47.9452	45	27	60.0000		
14	PLA	RESPMOOD	LVCF	0.43121	0.22746	0.8175	0.00995	104	42	40.3846	116	38	32.7586	*	
15	HAL	RESPANX	OBSERVED CASES	1.29289	0.75330	2.2190	0.35129	122	58	47.5410	131	78	59.5420		
16	HAL	RESPANX	LVCF	0.94565	0.61323	1.4582	0.80034	179	68	37.9888	229	99	43.2314		
17	HAL	RESPBPRS	OBSERVED CASES	1.04852	0.64126	1.7144	0.85019	139	70	50.3597	164	96	58.5366		
18	HAL	RESPBPRS	LVCF	0.96270	0.64271	1.4420	0.85372	196	72	36.7347	262	107	40.8397		
19	HAL	RESPFI	OBSERVED CASES	0.99822	0.59598	1.6719	0.99461	117	61	52.1368	151	83	54.9669		
20	HAL	RESPFI	LVCF	0.83100	0.55084	1.2537	0.37756	169	72	42.6036	260	106	40.7692		
21	HAL	RESPFV	OBSERVED CASES	1.16281	0.68557	1.9723	0.57577	132	80	60.6061	168	118	70.2381		
22	HAL	RESPFV	LVCF	1.20884	0.81128	1.8012	0.35127	194	89	45.8763	262	145	55.3435		
23	HAL	RESPHOST	OBSERVED CASES	0.86477	0.33671	2.2210	0.76272	52	34	65.3846	61	43	70.4918		
24	HAL	RESPHOST	LVCF	0.94621	0.47459	1.8865	0.87519	84	48	57.1429	94	59	62.7660		
25	HAL	RESPJMCK	OBSERVED CASES	0.97707	0.58892	1.6211	0.92845	135	78	57.7778	163	102	62.5767		
26	HAL	RESPJMCK	LVCF	0.84429	0.56630	1.2587	0.40617	193	84	43.5233	264	117	44.3182		
27	HAL	RESPMOOD	OBSERVED CASES	1.07406	0.64692	1.7832	0.78238	122	59	48.3607	151	82	54.3046		
28	HAL	RESPMOOD	LVCF	0.85891	0.57051	1.2931	0.46624	174	70	40.2299	262	104	39.6947		
29	CHL	RESPANX	OBSERVED CASES	0.85243	0.45192	1.6079	0.62191	79	47	59.4937	86	49	56.9767		
30	CHL	RESPANX	LVCF	0.97007	0.56382	1.6690	0.91260	97	49	50.5155	120	60	50.0000		
31	CHL	RESPBPRS	OBSERVED CASES	1.03509	0.56713	1.8892	0.91054	90	48	53.3333	109	62	56.8807		
32	CHL	RESPBPRS	LVCF	0.91834	0.54623	1.5439	0.74791	108	51	47.2222	148	70	47.2973		
33	CHL	RESPFI	OBSERVED CASES	0.82522	0.39631	1.7183	0.60770	66	47	71.2121	70	47	67.1429		
34	CHL	RESPFI	LVCF	0.83306	0.45998	1.5087	0.54668	83	49	59.0361	98	53	54.0816		
35	CHL	RESPFV	OBSERVED CASES	1.78671	0.93059	3.4304	0.08119	78	44	56.4103	100	72	72.0000		
36	CHL	RESPFV	LVCF	1.43833	0.84486	2.4487	0.18057	97	46	47.4227	142	83	58.4507		
37	CHL	RESPHOST	OBSERVED CASES	1.24363	0.48324	3.2005	0.65120	43	31	72.0930	56	42	75.0000		
38	CHL	RESPHOST	LVCF	1.15565	0.55359	2.4125	0.70006	52	33	63.4615	85	55	64.7059		

39	CHL	RESPJMCK	OBSERVED CASES	1.65117	0.86943	3.1358	0.12542	85	49	57.6471	99	70	70.7071		
40	CHL	RESPJMCK	LVCF	1.34230	0.79542	2.2652	0.27018	102	50	49.0196	141	81	57.4468		
41	CHL	RESPMOOD	OBSERVED CASES	0.86268	0.42215	1.7629	0.68541	69	48	69.5652	81	55	67.9012		
42	CHL	RESPMOOD	LVCF	1.15954	0.65175	2.0630	0.61456	88	49	55.6818	112	66	58.9286		
43	RIS	RESPANX	OBSERVED CASES	3.88134	1.37216	10.9789	0.01058	24	10	41.6667	64	45	70.3125	*	
44	RIS	RESPANX	LVCF	2.13994	0.88505	5.1741	0.09123	30	11	36.6667	94	50	53.1915		
45	RIS	RESPBPRS	OBSERVED CASES	7.78886	3.18149	19.0685	0.00001	33	11	33.3333	87	69	79.3103	*	
46	RIS	RESPBPRS	LVCF	5.11447	2.28449	11.4501	0.00007	38	11	28.9474	111	75	67.5676	*	
47	RIS	RESPFI	OBSERVED CASES	3.06761	1.21658	7.7349	0.01753	29	13	44.8276	60	43	71.6667	*	
48	RIS	RESPFI	LVCF	2.07549	0.91839	4.6904	0.07920	33	14	42.4242	90	55	61.1111		
49	RIS	RESPFV	OBSERVED CASES	7.49615	2.78970	20.1428	0.00006	29	14	48.2759	82	72	87.8049	*	
50	RIS	RESPFV	LVCF	3.27074	1.46442	7.3051	0.00385	33	14	42.4242	113	80	70.7965	*	
51	RIS	RESPHOST	OBSERVED CASES	0.85487	0.08322	8.7819	0.89504	6	5	83.3333	32	26	81.2500		
52	RIS	RESPHOST	LVCF	0.45404	0.04884	4.2213	0.48764	7	6	85.7143	41	30	73.1707		
53	RIS	RESPJMCK	OBSERVED CASES	8.23135	3.24559	20.8761	0.00001	33	14	42.4242	85	73	85.8824	*	
54	RIS	RESPJMCK	LVCF	4.16116	1.91339	9.0495	0.00032	38	14	36.8421	113	80	70.7965	*	
55	RIS	RESPMOOD	OBSERVED CASES	3.01674	1.19839	7.5941	0.01907	28	13	46.4286	72	53	73.6111	*	
56	RIS	RESPMOOD	LVCF	1.90436	0.85426	4.2453	0.11529	33	14	42.4242	104	62	59.6154		

OBS	COMP	END	ANAL	EST	LCL	UCL	P	SERN	SERR	SER%	COMPN	COMPR	COMP%	SIG
1	PLA	RESPANX	OBSERVED CASES	1.07810	0.71502	1.62556	0.71964	201	105	52.2388	217	127	58.5253	
2	PLA	RESPANX	LVCF	0.94935	0.67727	1.33075	0.76292	276	117	42.3913	349	159	45.5587	
3	PLA	RESPBPRS	OBSERVED CASES	1.04969	0.71774	1.53517	0.80255	229	118	51.5284	273	158	57.8755	
4	PLA	RESPBPRS	LVCF	0.95217	0.69252	1.30918	0.76289	304	123	40.4605	410	177	43.1707	
5	PLA	RESPFI	OBSERVED CASES	0.94098	0.61739	1.43419	0.77725	183	108	59.0164	221	130	58.8235	
6	PLA	RESPFI	LVCF	0.82950	0.59196	1.16237	0.27751	252	121	48.0159	358	159	44.4134	
7	PLA	RESPFV	OBSERVED CASES	1.40105	0.93230	2.10550	0.10466	210	124	59.0476	268	190	70.8955	
8	PLA	RESPFV	LVCF	1.28047	0.93198	1.75928	0.12717	291	135	46.3918	404	228	56.4356	
9	PLA	RESPHOST	OBSERVED CASES	1.03770	0.53400	2.01653	0.91305	95	65	68.4211	117	85	72.6496	
10	PLA	RESPHOST	LVCF	1.04078	0.62963	1.72042	0.87614	136	81	59.5588	179	114	63.6872	
11	PLA	RESPJMCK	OBSERVED CASES	1.20292	0.81050	1.78536	0.35910	220	127	57.7273	262	172	65.6489	
12	PLA	RESPJMCK	LVCF	0.99858	0.72775	1.37018	0.99297	295	134	45.4237	405	198	48.8889	
13	PLA	RESPMOOD	OBSERVED CASES	1.00575	0.66620	1.51835	0.97823	191	107	56.0209	232	137	59.0517	
14	PLA	RESPMOOD	LVCF	0.94434	0.67704	1.31716	0.73585	262	119	45.4198	374	170	45.4545	

Technical Document (TD004)

Approved for issue by:

Andrew Gorman
Project Team Physician
AstraZeneca Pharmaceuticals
Alderley Park
Macclesfield, Cheshire
SK10 4TG

Signature.....Date.....

Emma Westhead
Senior Statistician
AstraZeneca Pharmaceuticals
Alderley Park
Macclesfield, Cheshire
SK10 4TG

Signature.....Date.....